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observations have several notable implications. First,
the fact that most but not all Akt/PKB targets are still
phosphorylated in mTORC2 knockout MEFs suggests
that Ser473 phosphorylation determines Akt/PKB spec-
ificity rather than absolute activity. Second, since reduc-
tion in FoxO phosphorylation is the only observed Akt/
PKB signaling defect, does this defect alone account
for the embryonic lethality? Akt/PKB negatively regu-
lates FoxO. Reduced FoxO phosphorylation should
therefore lead to FoxO hyperactivation. FoxO transcrip-
tion factors control various target genes in a tissue-
dependent manner. It would be of interest to determine
which FoxO target genes are affected in the mTORC2
knockout MEFs, and to test whether disruption of
FoxO rescues the mTORC2-disrupted mice. Obviously,
it would also be of interest to look for other abnormalities
in the mTORC2-disrupted mice that might account
for the embryonic lethality. Third, the finding that Akt/
PKB Ser473 phosphorylation is not necessary for phos-
phorylation of TSC2, mTOR, and S6K solves a puzzle.
mTORC2 was assumed to regulate Akt/PKB activity
toward all its substrates, including TSC2, which nega-
tively regulates mTORC1. Thus, mTORC2 should acti-
vate mTORC1. However, contrary to this assumption,
mTORC2 knockdown was previously shown not to affect
the mTORC1 target S6K (Jacinto et al., 2004; Sarbassov
et al., 2004). We now know that Ser473 phosphorylation
is not required for Akt/PKB to signal to mTORC1. Thus,
mTORC2 is not upstream of mTORC1.
mTORC2, like yeast and Dictyostelium TORC2, has
been shown to regulate actin cytoskeleton organization.
However, Shiota et al. (2006) failed to observe an actin
defect in the rictor knockout MEFs. Shiota et al. (2006)
also point out that the rictor knockout mice seemed to
develop normally until day E9.5, including gastrulation,
neurulation, and formation of the cardiovascular sys-
tem—all of which require an intact actin cytoskeleton.
This could indicate that mTORC2 is not necessary for
regulation of actin cytoskeleton organization in vivo.
Still, actin defects following TORC2 disruption have
been detected in all organisms examined. It is possible
that mTORC2 becomes active in actin organization only
late in development, or that this mTORC2 function is
required only under specific conditions.
Although Jacinto et al. (2006) focus on the role of
mTORC2 in the regulation of Akt/PKB and Shiota et al.
(2006) focus on the role of mTORC2 in embryogenesis,
the two papers complement and support each other.
Together with the study from Frias et al. (2006), they
provide a major advance in our understanding of the
regulation of cell growth by mTORC2.
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A New Player in EMT
Epithelial mesenchymal transition (EMT) is a complex
process that involves changes in gene expression,
cytoskeleton organization, cell adhesion, and extra-
cellular matrix composition. Screening for genes
mediating EMT and cancer metastasis, Waerner, Ala-
cakaptan, and colleagues identified ILEI, a cytokine-
like protein that plays an essential role in EMT, tumor
growth, and late steps of metastasis.
Epithelial and mesenchymal cells exhibit distinct mor-
phological and functional characteristics (reviewed inThiery and Sleeman, 2006). In addition to a specific
gene expression pattern, epithelial cells display apical-
basal polarity manifested in the specific distribution of
cell-surface molecules, organization of cell-cell junc-
tions, polarized organization of the cytoskeleton and
formation of a basal lamina. In contrast to epithelial
cells, mesenchymal cells do not form an organized
cell layer; they do not polarize and can be highly
motile. Epithelial sheets can undergo a transition into
a mesenchyme in a process termed epithelial mesen-
chymal transition (EMT). EMT is characterized by repres-
sion of E-cadherin, gain of vimentin expression, and an
increase in cell motility. The transition from epithelium
to mesenchyme is important for diverse processes in-
volved in tissue formation and organogenesis during
embryonic development (Shook and Keller, 2003).
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435Table 1. ILEI Effect on EMT and Cancer Formation
Cell Line Ras Activity ILEI Expression EMTa Tumorigenesis Metastasis
EpH4, Spontaneously immortalized
mammary epithelial cells
-/+ -/+ 2 2 2
+ over-expressed + + +
inhibited by L739749 over-expressed 2 2 2
EpRasXT, Ras-transformed EpH4,
treated with TGFb to induce EMT
++ + + + +
++ inhibited by siRNA 2 2 2
Experimental manipulations are highlighted in italics.
a As assayed by decreased cadherin and increased vimentin expression.As opposed to the constructive role EMT plays during
normal development, deregulation of components that
control this process can promote tumorigenesis. A
prominent example for such a molecule is Twist, a tran-
scription factor that plays a critical role in tissue reorga-
nization during development (Castanon and Baylies,
2002) and has been implicated in promoting cancer
cell metastasis (Yang et al., 2004).
In the September issue ofCancerCell, Waerner, Alaca-
kaptan, et al. report of a screen for molecules involved in
EMT and cancer metastasis (Waerner et al., 2006). This
effort led to the identification of a novel interleukin-re-
lated protein (ILEI) whose function is necessary and suf-
ficient for EMT, tumorigenesis, and metastasis of normal
epithelial cells (Table 1). The identification of ILEI relied
on an expression-profiling assay that employs polysome
bound mRNAs. Unlike other expression profiling tech-
niques, this method allows the identification of RNAs
whose translation rather than their transcriptional profile
is correlated with the relevant process—EMT in this case
(Jechlinger et al., 2003; Pradet-Balade et al., 2001).
The level of translated and secreted ILEI was found to
be elevated in murine mammary epithelial cells that ex-
press oncogenic Ras protein and undergo EMT in re-
sponse to TGFb (termed ‘‘EpRasXT cells’’). To determine
whether ILEI alone is capable of inducing EMT, immortal-
ized epithelial cell (termed ‘‘EpH4’’) derivates were engi-
neered to overexpress the cytokine or were exposed to
exogenous ILEI (Table 1). Remarkably, treated cells ex-
hibited EMT as judged by loss of epithelial morphology
and gain of mesenchymal gene expression profile (e.g.,
reduction in E-cadherin and elevation in vimentin expres-
sion). The opposite effect could be observed when cells
that performed EMT in response to TGFb were treated
with siRNA directed against ILEI as the cells reacquired
characteristic epithelial morphology and gene expres-
sion (Table 1). To determine the signaling events associ-
ated with ILEI-induced EMT, the authors focused on the
Ras pathway, which had been previously implicated in
EMT induced by TGFb (Janda et al., 2002). Indeed,
EpH4 cell lines overexpressing ILEI exhibited a dramatic
increase in the level of Erk/MAPK activation. Conversely,
when the cells expressing ILEI were treated with a Ras
farnesylation inhibitor, EMT was reverted lending further
support to the notion that ILEI-induced EMT requires ac-
tivation of the Ras-signaling pathway (Table 1). The bio-
chemical cascade in which ILEI participates appears to
play a central role in EMT as depletion of ILEI abrogates
EMT induced by other means, such as TGFb expression.
Importantly, the biological function of ILEI was found to
be of relevance for tumor formation and metastasis. Spe-
cifically, whereas EpH4 cells are not tumorigenic, ILEIoverexpression enabled the cells to form tumors when
injected into nude mice. Interestingly, cells derived
from these tumors showed the characteristic low E-cad-
herin and high vimentin expression profile indicating that
they underwent EMT in vivo. Introduction of ILEI overex-
pressing cells directly into the blood by tail vein injection
allowed late stages of metastasis (e.g., extravasation, in-
vasion, and proliferation at distant sites) to be examined.
Significantly, it was demonstrated that most of the mice
injected with an originally nonmetastatic EpH4-derived
cell line that was engineered to overexpress ILEI devel-
oped metastasis. In this context, the finding that ILEI
overexpression results in upregulation of multiple che-
mokines, cytokines, and growth factor receptors is sig-
nificant. These other molecules could facilitate homing
of the metastatic cells to their targets and promote cell
growth at these locations (e.g., Muller et al., 2001; Orimo
et al., 2005).
Last, the authors could demonstrate a correlation be-
tween formation of carcinomas, which are malignancies
originating in epithelial tissues, and ILEI overexpres-
sion. This finding is especially important considering
that carcinomas are the most common type of cancer
in humans. Human carcinomas exhibited elevated
levels of the ILEI protein in the cytoplasm. Cytoplasmic
ILEI, believed to be the fraction of the protein undergo-
ing secretion, was particularly evident at the invasion
front, which is the part of the tumor undergoing EMT.
Importantly, strong cytoplasmic ILEI expression in tu-
mors was shown to correlate with increased metastasis
and decreased patient survival. Therefore, ILEI expres-
sion and its subcellular localization could serve as clin-
ical markers for tumor progression. Significantly, cyto-
plasmic ILEI staining did not appear to correlate with a
previously described set of clinical markers for poor
prognosis. ILEI could thus represent a novel tool for di-
agnostics and treatment of certain carcinomas. These
findings highlight the importance of determining the
protein expression level and localization in the tumor
cells; transcription profiling would be ineffective for
‘‘ILEI-like’’ cases where the main control over the func-
tion of gene is exerted posttranscriptionally.
A particularly intriguing question concerns the func-
tion of ILEI in normal development and adult life. As
it defines a new class of EMT regulators, it would be
interesting to examine the expression pattern of the
protein and its subcellular distribution during processes
such as tissue and single cell migration, when cells
leave, invade, or integrate into other tissues. Phenotypic
analysis of animals in which the activity of ILEI is com-
promised would provide important clues regarding its
role in these processes. As more developmentally
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transcriptional control are being identified, this study
provides a further motivation to apply tools for gene
identification that take these modes of regulation into
consideration.
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DEP Domains:
More Than JustMembraneAnchors
The DEP domain is present in a number of signaling
molecules, including Regulator of G protein Signaling
(RGS) proteins, and has been implicated in membrane
targeting. New findings in yeast, however, demon-
strate a major role for a DEP domain in mediating
the interaction of an RGS protein to the C-terminal
tail of a GPCR, thus placing RGS in close proximity
with its substrate G protein a subunit.
G protein-coupled receptors (GPCRs) transduce extra-
cellular cues through their cognate G proteins, which
consist of three subunits, a, b, and g, that form a hetero-
trimeric complex (Hamm, 1998). Given the critical role of
GPCRs in mediating divergent functions of cells and
their adaptation to the environment, it is not surprising
that GPCR signaling is subjected to stringent control.
Whereas the binding of ligands to receptors initiates
signals that are amplified through G proteins and effec-
tors, it also activates negative feedback mechanisms to
desensitize signaling. These negative feedback regula-
tions act at almost every step of signal transmission,
starting from the receptor. Key players in these desen-
sitization processes are regulator of G protein signal
(RGS) proteins, which decrease the intensity and limit
the duration of G protein signaling by stimulating the
intrinsic GTPase activities of Ga subunits (Abramow-
Newerly et al., 2006).
The core RGS domain confers GTPase-activator pro-
tein (GAP) activity. It has been known for some time that
many RGS proteins show little GAP selectivity toward
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ner in vivo. Recent studies indicate that the answer to
these paradoxical findings may lie in additional domains
of RGS proteins that bind to other cellular proteins and
promote substrate specificity of the RGS GAP domain.
In a study published recently in Cell, Ballon and col-
leagues demonstrated that the DEP domain contained
in the N-terminal extension of a yeast RGS protein,
Sst2, mediates the interaction of Sst2 with the
C-terminal tail of its cognate GPCR Ste2, thus placing
Sst2 in the vicinity of its substrate Ga subunit Gpa1
(Ballon et al., 2006).
The DEP domain is a stretch of w90 conserved resi-
dues that was first identified in three proteins, Dishev-
eled, EGL-10, and Pleckstrin (Ponting and Bork, 1996).
Highly homologous domains are also found in a number
of proteins involved in signal transduction, such as
Epac2, yeast RGS protein Sst2, and the R7 subfamily
(RGS6, 7, 9, and 11) of mammalian RGS proteins.
Earlier studies in several proteins have pointed out a
function for DEP domains in mediating membrane
localization (Wong et al., 2000). Recent data indicate
that the DEP domain of RGS9-2 directs its RGS activity
toward D2 dopamine, but not M2 muscarinic receptor-
mediated signaling pathways (Kovoor et al., 2005).
However, the molecular mechanisms underlying this
DEP domain-dependent selectivity are unknown.
Ballon et al. (2006) set out to identify binding partners
of the DEP domain in Sst2, a yeast RGS protein. They
screened a library of overexpressed genes to identify
proteins that can suppress the defect in pheromone
responses caused by a point mutation in the DEP do-
main of Sst2. Surprisingly, they pulled out the a-factor
receptor Ste2. Using a combination of biochemical,
genetic, and cell imaging approaches, they have con-
firmed an interaction between Sst2 and Ste2 and dem-
onstrated that this interaction is mediated by the DEP
